Canaccord Genuity initiated coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research note released on Tuesday, August 7th, MarketBeat reports. The brokerage issued a buy rating and a $55.00 price target on the stock.
A number of other research firms have also recently commented on DCPH. JMP Securities increased their price target on shares of Deciphera Pharmaceuticals to $65.00 and gave the company an outperform rating in a report on Tuesday, June 19th. B. Riley cut shares of Deciphera Pharmaceuticals from a buy rating to a neutral rating and set a $43.00 target price on the stock. in a report on Tuesday, June 19th. SunTrust Banks initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Thursday, July 5th. They issued a buy rating on the stock. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, July 3rd. Finally, Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, June 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. Deciphera Pharmaceuticals currently has a consensus rating of Buy and an average target price of $50.10.
Shares of NASDAQ DCPH traded down $0.32 on Tuesday, reaching $36.99. 150,200 shares of the company’s stock traded hands, compared to its average volume of 194,584. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $45.61. The company has a market capitalization of $1.44 billion and a price-to-earnings ratio of -12.39. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after acquiring an additional 1,982 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Deciphera Pharmaceuticals by 37.5% in the 1st quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after buying an additional 2,700 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter worth $203,000. Schwab Charles Investment Management Inc. grew its stake in shares of Deciphera Pharmaceuticals by 20.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 33,791 shares of the company’s stock worth $678,000 after buying an additional 5,737 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 1st quarter worth $152,000. Institutional investors own 53.49% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.